Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REACH-1: Ruxolitinib + Corticosteroids for Steroid-Refractory Acute GVHD
NCT02953678Phase 2Completed
- Sponsor
- Incyte
- Start
- Dec 2016
- Primary completion
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ruxolitinib in Acute Graft-Versus-Host Disease (aGvHD), sponsored by Incyte. Primary endpoint: Overall Response Rate at Day 28. Started Dec 2016; status: completed.
02
Drugs
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT02953678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02953678.